EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?

Giorgia Grassi iD, Alberto Ghielmetti, Marta Zampogna, Iacopo Chiodini iD, Maura Arosio iD, Giovanna Mantovani iD, Cristina Eller-Vainicher

The Journal of Clinical Endocrinology & Metabolism · 16.09.2024 · 109 (10) · e1817-e1826

DOI: 10.1210/clinem/dgae224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 13.04.2024. Verfasst von Giorgia Grassi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. Hauptthemen laut MEDLINE: Zoledronic Acid, Denosumab, Bone Density Conservation Agents, Bone Density. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ricerca Corrente, Italian Ministry of Health to Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

After denosumab (Dmab) discontinuation C-terminal telopeptide (CTX) levels increase, bone mineral density (BMD) decreases and multiple vertebral fractures (FX) may occur with relevant impacts on women's health. A sequential therapy with bisphosphonates is recommended, and the European Calcified Tissue Society (ECTS) proposed repeated zoledronate (ZOL) administrations in patients with persistently high CTX levels, although the efficacy of this schedule is unknown. In this retrospective study, we describe BMD changes and FX rate in 52 patients managed according to the ECTS recommendations.

Methods

We measured CTX levels and administered ZOL after 1 month from Dmab withdrawal (t0). After 6 months (t1), we administered a second ZOL infusion, if CTX levels were ≥280 ng/L. BMD changes and FX rate were assessed on average after 17 months from Dmab withdrawal.

Results

Seventy-five percent of patients repeated ZOL infusion. In this group, spine BMD declined significantly (−5.5 ± 5.6%), while it remained stable in the group with CTX levels <280 ng/L (−0.1 ± 5.5%, P = 0.008). All fractured patients (9.6%) had received >5 Dmab injections and 2 ZOL infusions. The BMD worsening after Dmab withdrawal was associated with CTX t1 [odds ratio (OR) 2.9, interquartile range (IQR) 1.3-6.6, P = .009] and spine BMD gain during Dmab therapy corrected for the number of Dmab injections (OR 3.0, IQR 1.2-7.2, P = .014). A CTX level at t1 > 212 ng/L had 100% sensitivity in predicting the BMD loss.

Conclusion

In patients with uncontrolled CTX levels after Dmab withdrawal, 2 ZOL infusions 6 months apart do not prevent BMD loss and FX.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zoledronic AcidDenosumabBone Density Conservation AgentsBone DensityHumansFemaleAgedRetrospective StudiesMiddle AgedAged, 80 and overDrug Administration ScheduleSpinal FracturesTreatment OutcomeDiphosphonatesWithholding TreatmentMaleCollagen Type IPeptides

Stichwörter der Autor:innen

bone turnover markersdenosumab withdrawalosteoporosisrebound effectsequential therapyzoledronate

Substanzen

Zoledronic AcidDenosumabBone Density Conservation AgentsDiphosphonatesCollagen Type Icollagen type I trimeric cross-linked peptidePeptides

Autor:innen und Institutionen

  • Endocrine Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
  • Department of Clinical Sciences and Community Health, University of Milan, 20100 Milan, Italy.
  • Department of Medical Biotechnology and Translational Medicine, University of Milan, 20100 Milan, Italy.
  • Unit of Endocrinology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.

ORCID-Profile: Giorgia Grassi, Iacopo Chiodini, Maura Arosio, Giovanna Mantovani

Förderung

  • Ricerca Corrente
  • Italian Ministry of Health to Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Zitieren

APA

Grassi, G., Ghielmetti, A., Zampogna, M., Chiodini, I., Arosio, M., Mantovani, G., & Eller-Vainicher, C. (2024). Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?. The Journal of Clinical Endocrinology & Metabolism, 109(10), e1817-e1826. https://doi.org/10.1210/clinem/dgae224

Vancouver

Grassi G, Ghielmetti A, Zampogna M, Chiodini I, Arosio M, Mantovani G, et al. Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?. The Journal of Clinical Endocrinology & Metabolism. 2024;109(10):e1817-e1826. doi:10.1210/clinem/dgae224

BibTeX
@article{Grassi2024,
  author = {Grassi, Giorgia and Ghielmetti, Alberto and Zampogna, Marta and Chiodini, Iacopo and Arosio, Maura and Mantovani, Giovanna and Eller-Vainicher, Cristina},
  title = {Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {109},
  number = {10},
  pages = {e1817--e1826},
  doi = {10.1210/clinem/dgae224}
}
Kostenlos starten →